These results indicate that delivery of low-dose TSA directly impairs the tumor-promoting activity of immunosuppressive macrophages, suggesting that the epigenetic rewiring of macrophages by HDAC inhibition may empower TAMs anti-tumor activities. The gene discussed is HDAC9; the disease is neoplasm.